The campaign highlights the crossover that Lilly sees between its own 150 years of working toward scientific progress and the ...

Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance.

The Indianapolis-based drugmaker reported revenue of $19.3 billion — up 43% from the same period a year ago, driven by growth ...

The market for obesity drugs may soon reach almost $100 billion.

The stock price has climbed in the triple digits over three years.

Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is ...

One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of ...

We recently published 10 Stocks With Monster Gains. Eli Lilly and Company (NYSE:LLY) was one of the top performers on ...

Eli Lilly has surged 47% since my last article, exceeding my previous $800 price target and reaching all-time highs near $1,030. LLY's leadership in the obesity treatment market continues to drive top ...

Eli Lilly stock delivered ~40% since my initial bullish article. Novo pressures with oral Semaglutide and CagriSema, but that is just a timing issue before Retatrutide + Orforglipron take the stage.